4.6 Article

Disparities in breast cancer: a multi-institutional comparative analysis focusing on American Hispanics

Journal

CANCER MEDICINE
Volume 7, Issue 6, Pages 2710-2717

Publisher

WILEY
DOI: 10.1002/cam4.1509

Keywords

African American; Breast Cancer; Disparities; Ethnic differences; Hispanic; Hormone Receptor; Triple Negative

Categories

Ask authors/readers for more resources

Breast cancer (BC) is the leading cause of cancer death in Hispanic/Latino women nationwide. Hispanic women are more likely to be presented with advanced disease and adverse prognosis subtypes. The aim of this study is to describe the clinico-pathological characteristics and disparities in breast cancer in this group at two tertiary care University-based medical centers. After IRB approval, Cancer registry was used to analyze the variables of 3441 patients with breast cancer diagnosed and treated consecutively at two large tertiary University based medical and cancer center database centers in El Paso, TX and Loma Linda, CA between 2005 and 2015. Association between race/ethnicity and cancer type, stage, hormone receptor status and treatment option were investigated. Overall 45.5% of the patients were Hispanic (n: 1566) and those were more likely to be diagnosed at a younger age (57 years) similar to African Americans, more likely to have invasive ductal carcinoma type (82.7%) & triple negative disease (17.1%, 95%CI: 15% to 19%). 58.8% of Hispanics (95%CI: 56% to 61%) have hormone receptor (HR)+ & HER2- as opposed to 71% in non-Hispanic White people. In addition, Hispanic individuals presented with advanced stages of BC (25.3%, 95% CI: 23% to 28%) similar to African American (25.4%), and had a lower proportion of lumpectomy (50%) similar to African American (50%). When compared to African American patients, Hispanic patients had a higher prevalence of triple negative BC (17.11% in Hispanics Versus 13.86% in African American). Conclusion: Hispanics had significantly higher relative risk of advanced stages at presentation (Relative Risk Ratio (RRR) = 2.05, P < 0.001), triple negative tumors (RRR = 2.64, P < 0.0001), HER2+/HR - disease (RRR = 1.77, P < 0.0001), and less HR+ /HER2- BC (RRR = 0.69, P < 0.0001). Hispanics and African Americans are diagnosed with breast cancer at a younger age, have a higher prevalence of Triple negative breast cancer, and are diagnosed at more advanced stages of disease. Increasing awareness and targeting minority populations for health promotion interventions, screening and early detection continue to be of paramount importance to reduce the burden of health disparities.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer

Cynthia X. Ma, Jingqin Luo, Michael Naughton, Foluso Ademuyiwa, Rama Suresh, Malachi Griffith, Obi L. Griffith, Zachary L. Skidmore, Nicholas C. Spies, Avinash Ramu, Lee Trani, Timothy Pluard, Gayathri Nagaraj, Shana Thomas, Zhanfang Guo, Jeremy Hoog, Jing Han, Elaine Mardis, Craig Lockhart, Matthew J. Ellis

CLINICAL CANCER RESEARCH (2016)

Article Cell Biology

AhR ligand aminoflavone suppresses α6-integrin-Src-Akt signaling to attenuate tamoxifen resistance in breast cancer cells

Petreena S. Campbell, Nicole Mavingire, Salma Khan, Leah K. Rowland, Jonathan V. Wooten, Anna Opoku-Agyeman, Ashley Guevara, Ubaldo Soto, Fiorella Cavalli, Andrea Irene Loaiza-Perez, Gayathri Nagaraj, Laura J. Denham, Olayemi Adeoye, Brittany D. Jenkins, Melissa B. Davis, Rachel Schiff, Eileen J. Brantley

JOURNAL OF CELLULAR PHYSIOLOGY (2019)

Article Medicine, General & Internal

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah, Yu Shyr, Samuel M. Rubinstein, Donna R. Rivera, Sanjay Shete, Chih-Yuan Hsu, Aakash Desai, Gilberto de Lima Lopes, Petros Grivas, Corrie A. Painter, Solange Peters, Michael A. Thompson, Ziad Bakouny, Gerald Batist, Tanios Bekaii-Saab, Mehmet A. Bilen, Nathaniel Bouganim, Mateo Bover Larroya, Daniel Castellano, Salvatore A. Del Prete, Deborah B. Doroshow, Pamela C. Egan, Arielle Elkrief, Dimitrios Farmakiotis, Daniel Flora, Matthew D. Galsky, Michael J. Glover, Elizabeth A. Griffiths, Anthony P. Gulati, Shilpa Gupta, Navid Hafez, Thorvardur R. Halfdanarson, Jessica E. Hawley, Emily Hsu, Anup Kasi, Ali R. Khaki, Christopher A. Lemmon, Colleen Lewis, Barbara Logan, Tyler Masters, Rana R. McKay, Ruben A. Mesa, Alicia K. Morgans, Mary F. Mulcahy, Orestis A. Panagiotou, Prakash Peddi, Nathan A. Pennell, Kerry Reynolds, Lane R. Rosen, Rachel Rosovsky, Mary Salazar, Andrew Schmidt, Sumit A. Shah, Justin A. Shaya, John Steinharter, Keith E. Stockerl-Goldstein, Suki Subbiah, Donald C. Vinh, Firas H. Wehbe, Lisa B. Weissmann, Julie Tsu-Yu Wu, Elizabeth Wulff-Burchfield, Zhuoer Xie, Albert Yeh, Peter P. Yu, Alice Y. Zhou, Leyre Zubiri, Sanjay Mishra, Gary H. Lyman, Brian Rini, Jeremy L. Warner

LANCET (2020)

Article Medicine, General & Internal

Association of Sociodemographic Factors With Immunotherapy Receipt for Metastatic Melanoma in the US

Justin T. Moyers, Amie Patel, Wendy Shih, Gayathri Nagaraj

JAMA NETWORK OPEN (2020)

Review Medicine, Research & Experimental

Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review

Gayathri Nagaraj, Cynthia X. Ma

Summary: Endocrine therapy is crucial for treating hormone receptor-positive, HER2-negative metastatic breast cancer, but its efficacy can be limited by resistance mechanisms. Recent developments have led to CDK4/6 inhibitors becoming standard care, but the optimal sequencing of treatments remains unknown, especially after disease progression.

ADVANCES IN THERAPY (2021)

Article Oncology

Real world outcomes of combination and timing of immunotherapy with radiotherapy for melanoma with brain metastases

Justin T. Moyers, Esther G. Chong, Jiahao Peng, Hsin Hsiang Clarence Tsai, Daniel Sufficool, David Shavlik, Gayathri Nagaraj

Summary: The study showed that patients with melanoma with brain metastasis who received immunotherapy and radiotherapy combination treatment had longer survival. Patients receiving concurrent immunotherapy and radiotherapy showed better survival compared to those receiving radiotherapy alone.

CANCER MEDICINE (2021)

Article Oncology

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

P. Grivas, A. R. Khaki, T. M. Wise-Draper, B. French, C. Hennessy, C-Y Hsu, Y. Shyr, X. Li, T. K. Choueiri, C. A. Painter, S. Peters, B. Rini, M. A. Thompson, S. Mishra, D. R. Rivera, J. D. Acoba, M. Z. Abidi, Z. Bakouny, B. Bashir, T. Bekaii-Saab, S. Berg, E. H. Bernicker, M. A. Bilen, P. Bindal, R. Bishnoi, N. Bouganim, D. W. Bowles, A. Cabal, P. F. Caimi, D. D. Chism, J. Crowell, C. Curran, A. Desai, B. Dixon, D. B. Doroshow, E. B. Durbin, A. Elkrief, D. Farmakiotis, A. Fazio, L. A. Fecher, D. B. Flora, C. R. Friese, J. Fu, S. M. Gadgeel, M. D. Galsky, D. M. Gill, M. J. Glover, S. Goyal, P. Grover, S. Gulati, S. Gupta, S. Halabi, T. R. Halfdanarson, B. Halmos, D. J. Hausrath, J. E. Hawley, E. Hsu, M. Huynh-Le, C. Hwang, C. Jani, A. Jayaraj, D. B. Johnson, A. Kasi, H. Khan, V. S. Koshkin, N. M. Kuderer, D. H. Kwon, P. E. Lammers, A. Li, A. Loaiza-Bonilla, C. A. Low, M. B. Lustberg, G. H. Lyman, R. R. McKay, C. McNair, H. Menon, R. A. Mesa, V Mico, D. Mundt, G. Nagaraj, E. S. Nakasone, J. Nakayama, A. Nizam, N. L. Nock, C. Park, J. M. Patel, K. G. Patel, P. Peddi, N. A. Pennell, A. J. Piper-Vallillo, M. Puc, D. Ravindranathan, M. E. Reeves, D. Y. Reuben, L. Rosenstein, R. P. Rosovsky, S. M. Rubinstein, M. Salazar, A. L. Schmidt, G. K. Schwartz, M. R. Shah, S. A. Shah, C. Shah, J. A. Shaya, S. R. K. Singh, M. Smits, K. E. Stockerl-Goldstein, D. G. Stover, M. Streckfuss, S. Subbiah, L. Tachiki, E. Tadesse, A. Thakkar, M. D. Tucker, A. K. Verma, D. C. Vinh, M. Weiss, J. T. Wu, E. Wulff-Burchfield, Z. Xie, P. P. Yu, T. Zhang, A. Y. Zhou, H. Zhu, L. Zubiri, D. P. Shah, J. L. Warner, GdL Lopes

Summary: This study analyzed clinical factors and laboratory measurements of cancer patients with COVID-19, finding that factors such as age, sex, comorbidities, cancer type, and laboratory results were associated with COVID-19 severity. Patients diagnosed early in the pandemic had worse outcomes, and specific anticancer therapies may increase 30-day all-cause mortality. More research is needed to confirm these findings and caution may be needed in using certain anticancer treatments.

ANNALS OF ONCOLOGY (2021)

Article Oncology

Proton stereotactic body radiation therapy for liver metastases- results of 5-year experience for 81 hepatic lesions

Alex R. Coffman, Daniel C. Sufficool, Joseph Kang, Chung-Tsen Hsueh, Sasha Swenson, Patrick Q. McGee, Gayathri Nagaraj, Baldev Patyal, Mark E. Reeves, Jerry D. Slater, Gary Y. Yang

Summary: This study retrospectively analyzed the institutional experience of using Proton stereotactic body radiation therapy (SBRT) for liver metastases from September 2012 to December 2017. The results showed promising local control rates and low toxicity, indicating the potential to safely treat multiple lesions with Proton SBRT.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)

Article Oncology

Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study

Michael J. Wagner, Cassandra Hennessy, Alicia Beeghly, Benjamin French, Dimpy P. Shah, Sarah Croessmann, Diana Vilar-Compte, Erika Ruiz-Garcia, Matthew Ingham, Gary K. Schwartz, Corrie A. Painter, Rashmi Chugh, Leslie Fecher, Cathleen Park, Olga Zamulko, Jonathan C. Trent, Vivek Subbiah, Ali Raza Khaki, Lisa Tachiki, Elizabeth S. Nakasone, Elizabeth T. Loggers, Chris Labaki, Renee Maria Saliby, Rana R. McKay, Archana Ajmera, Elizabeth A. Griffiths, Igor Puzanov, William D. Tap, Clara Hwang, Sachin R. Jhawar, Brandon Hayes-Lattin, Elizabeth Wulff-Burchfield, Anup Kasi, Daniel Y. Reuben, Gayathri Nagaraj, Monika Joshi, Hyma Polimera, Amit A. Kulkarni, Khashayar Esfahani, Daniel H. Kwon, Luca Paoluzzi, Mehmet A. Bilen, Eric B. Durbin, Petros Grivas, Jeremy L. Warner, Elizabeth J. Davis

Summary: Patients with sarcoma have a higher risk of developing complications from COVID-19, and patients with bone sarcoma may be at a greater risk of death from COVID-19. Older age, poor performance status, and lung metastases are risk factors for more severe COVID-19.

CANCERS (2022)

Article Oncology

Hemolytic Anemia of Malignancy: A Case Study Involving Signet Ring Cell Metastatic Breast Cancer with Severe Microangiopathic Hemolytic Anemia

Eric H. Lee, Salman Otoukesh, Amir Abdi Pour, Gayathri Nagaraj

CASE REPORTS IN ONCOLOGY (2019)

Article Hematology

Acquired factor VII deficiency causing severe bleeding disorder secondary to AL amyloidosis of the liver

Anthony L. Nguyen, Muhammad Kamal, Ravi Raghavan, Gayathri Nagaraj

HEMATOLOGY REPORTS (2018)

Review Oncology

Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature

Shagufta Shaheen, Hamid Mirshahidi, Gayathri Nagaraj, Chung-Tsen Hsueh

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2018)

Article Medicine, General & Internal

Atypical Presentation of Gelsolin Amyloidosis in a Man of African Descent with a Novel Mutation in the Gelsolin Gene

Karlos Z. Oregel, Geoffrey P. Shouse, Cyrus Oster, Freddy Martinez, Jun Wang, Michael Rosenzweig, Jeremy K. Deisch, Chien-Shing Chen, Gayathri Nagaraj

AMERICAN JOURNAL OF CASE REPORTS (2018)

No Data Available